TD Cowen Remains Bullish on Amicus Therapeutics (FOLD) With a $20 PT
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the 13 Best Healthcare Stocks to Buy Under $10. On May 1, analyst Ritu Baral from TD Cowen maintained a Buy rating on Amicus Therapeutics, Inc. (NASDAQ:FOLD), keeping the price target at $20.00.
Doctors in a lab coat attending to a patient receiving enzyme replacement therapies.
The analyst based the rating on the company’s future growth potential and strategic positioning, stating that Amicus Therapeutics, Inc. (NASDAQ:FOLD) has maintained a positive outlook for GAAP profitability in H2 2025.
This trend emerged despite the Q1 revenue misses for both PomOp and Galafold, which were affected by higher UK VPAG rebates. Baral thus reasoned that these trends suggest confidence in the company’s operations and its ability to manage costs and drive future profitability.
Another factor supporting the analyst’s positive rating is Amicus Therapeutics, Inc.’s (NASDAQ:FOLD) pipeline expansion, especially with the in-licensing of DMX-200 for FSGS. This highlights the company’s commitment to boosting its long-term growth prospects and expanding its product offerings, according to Baral.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) discovers, develops, and delivers medicines to treat metabolic diseases. Its product portfolio includes the first and only approved oral precision medicine to treat Fabry disease, a clinical-stage treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.
While we acknowledge the potential of FOLD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.